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Neutrophil-like HL-60 cellsThe neutrophil NADPH oxidase (NOX2) is a key enzyme responsible for host defense against invading
pathogens, via the production of reactive oxygen species. Dysfunction of NOX2 can contribute to
inﬂammatory processes, which could lead to the development of diseases such as atherosclerosis. In this
paper, we characterize a pathway leading to NOX2 activation in which iPLA2-regulated p38 MAPK activity is
a key regulator of S100A8/A9 translocation via S100A9 phosphorylation. Studies in cell-free or recombinant
systems involved two Ca2+-binding proteins of the S100 family, namely S100A8 and S100A9, in NOX2
activation dependent on intracellular Ca2+ concentration ([Ca2+]i) elevation. Using differentiated HL-60 cells
as a model of neutrophils, we provide evidence that [Ca2+]i-regulated S100A8/A9 translocation is mediated
by an increase in [Ca2+]i through intracellular Ca
2+ store depletion. Moreover, we conﬁrm that p38 MAPK
induces S100A9 phosphorylation, a mandatory precondition for S100 translocation. Based on a
pharmacological approach and an siRNA strategy, we identify iPLA2 as a new molecular player aiding
S100 translocation and NOX2 activity. Inhibition of p38 MAPK activity and S100A9 phosphorylation by
bromoenol lactone, a selective inhibitor of iPLA2, indicated that p38 MAPK-mediated S100A9 phosphoryla-
tion is dependent on iPLA2. In conclusion, we have characterized a pathway leading to NOX2 activation in
which iPLA2-regulated p38 MAPK activity is a key regulator of S100A8/A9 translocation via S100A9
phosphorylation.r-2; BAPTA, 1,2-bis(o-amino-
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Neutrophils play an important role in defending their hosts against
microbial pathogens by generating reactive oxygen species through the
multicomponent enzyme NADPH oxidase (NOX2). Under pathophysi-
ological conditions, NOX2 activity can persist at a high level. The large
production of reactive oxygen species can cause tissue injury,
potentially leading to the development of inﬂammatory diseases such
as atherosclerosis or rheumatoid arthritis [1,2]. NOX2 activity has been
shown to be regulated by intracellular Ca2+ concentration ([Ca2+]i)
increase [3,4]. In neutrophils, the elevation of [Ca2+]i is primarily due to
intracellular Ca2+ store depletion-mediated Ca2+ inﬂux [5]. Recently,
S100A8 and S100A9, two members of the S100 family of Ca2+-binding
proteins [6] have been proposed as Ca2+-dependent regulators of NOX2activity [7–10]. S100A8 and S100A9 are able to form Ca2+-dependent
heterodimers and heterotetramers [11–13], the latter being probably
the biologically active form in myeloid cells [14]. However, the precise
link between [Ca2+]i elevation, S100A8/A9 and regulation of NOX2
activity was not clearly delineated in a cellular model.
Since S100A8 and S100A9 are secreted upon stimulation [15],
numerous extracellular functions have been attributed to these proteins,
in particular, the mediation of neutrophil adhesion to ﬁbronectin [16]
and the induction of neutrophil chemotaxis [17]. Also, because S100A8
and S100A9 are up-regulated in diseases such as bronchitis, cystic
ﬁbrosis, rheumatoid arthritis and Crohn's disease, these proteins are
largely used as markers of inﬂammation [18,19]. In addition to their
extracellular functions, S100A8 and S100A9 are also involved in
intracellular signaling pathways. The relevant role for S100A8/A9
complex has been established in NOX2 activation and is probably
mediated via its translocation to the plasma membrane. Further, it has
been suggested that the S100A8/A9 complex migrates from the cytosol
to membrane structures and intermediate ﬁlaments in a Ca2+-
dependent fashion, which has been correlated to phagocytic activation
[20–22].
However, several studies have revealed that Ca2+ concentration is
probably not the sole factor controlling the regulation of S100A8/A9
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that S100A9 translocated at the base of lamellipodia after stimulationby
the bacterial chemopeptide fMLF. Lominadze et al. [23] also demon-
strated that this translocation was dependent on S100A9 phosphory-
lation. Inaddition, researchhas revealed that S100A9phosphorylation is
mediated by p38 MAPK [23,24] and that p38 MAPK can be activated in
neutrophils [25]. Beckett et al. [26] showed thatp38MAPKactivity could
be altered byCa2+-independent phospholipaseA2 (iPLA2) in ventricular
myocytes. The hypothesis that iPLA2 contributes to S100A9 phosphor-
ylation and subsequent S100A8/A9 complex translocation to the cell
membrane, has not yet been explored.
The aim of the present study is to characterize the regulatory
pathways leading to S100A8/A9 translocation and subsequent regula-
tion of NOX2 activation in differentiated HL-60 cells (dHL-60 cells), a
model of neutrophils. Our data conﬁrm that S100A9 phosphorylation
and [Ca2+]i changes are two events required for S100A8/A9 transloca-
tion. In addition, we provide evidence that [Ca2+]i elevation-regulated
S100A8/A9 translocation is triggered by Ca2+ release from internal
stores. In addition, we demonstrate that both p38 MAPK and iPLA2 are
involved in S100A9 phosphorylation and that activation of p38 MAPK
occurs downstream of iPLA2 activation. Finally, we establish for the ﬁrst
time that iPLA2 is an essential regulator of S100A8/A9 translocation-
dependent NOX2 activity.
2. Materials and methods
2.1. Materials
The RPMI-1640 medium, fetal bovine serum, L-glutamine, penicil-
lin and streptomycin were purchased from Lonza (Verviers, Belgium).
N-formyl-L-Methionyl-L-Leucyl-L-Phenylalanine (fMLF), phorbol 12-
myristoyl 13-acetate (PMA), thapsigargin, ethylene glycol-bis (beta-
aminoethyl ether) N, N, N′, N′-tetraacetic acid (EGTA), ionomycin,
DMSO, horseradish peroxidase (HRP) type II, SB203580, bromoenol
lactone (BEL) and genistein were obtained from Sigma-Aldrich
(Bornem, Belgium). Fura-2 acetoxymethylester (fura-2-AM), 10-
acetyl-3,7-dihydroxyphenoxazine (Amplex Red) and 1,2-bis(o-ami-
nophenoxy)ethane-N, N, N′, N′-tetraacetic acid acetoxymethylester
(BAPTA-AM) were obtained from Invitrogen (Merelbeke, Belgium).
All other chemicals were of analytical grade and obtained fromMerck
(Darmstadt, Germany). The physiological salt solution (PSS) used had
the following composition: NaCl 115 mM, KCl 5 mM, KH2PO4 1 mM,
glucose 10 mM, MgSO4 1 mM, CaCl2 1.25 mM, HEPES-Na 25 mM,
which was supplemented with bovine serum albumin (BSA) 0.1% w/
v, pH 7.4.
2.2. Cell culture
The promyelocytic cell line HL-60 (ATCC #CCL-240) [27] was
grown in RPMI-1640 medium supplemented with 10% heat-inacti-
vated fetal bovine serum, L-glutamine (2 mM), streptomycin (100 µg/
mL) and penicillin (100 U/mL). The cells were kept at 37 °C, in a
humid, 5% CO2 atmosphere. The cells were sub-cultivated twice a
week. The differentiation of these cells to neutrophil-like cells was
induced by the addition of DMSO (ﬁnal concentration of 1.3% v/v) for
4.5 days [28].
2.3. RNA interference assays
Speciﬁc sequences of 19 nucleotides of human S100A8 or S100A9
cDNA were selected for the synthesis of small interfering RNAs
(siRNA). The pre-annealed siRNAs for S100A8, S100A9, iPLA2 and a
non-silencing control were custom-ordered from Eurogentec (Sera-
ing, Belgium). The siRNA sequence for S100A8 was GACCGAGUGUC-
CUCAGUAU (forward) and AUACUGAGGACACUCGGUC (reverse)
corresponding to the nucleotides 117 to 135. For the S100A9 siRNAthe sequences chosen were AAGAGCUGGUGCGAAAAGA (forward)
and UCUUUUCGCACCAGCUCUU (reverse) corresponding to the
nucleotides 113 to 131. To knock down iPLA2 a mix of two siRNA
was used: CUACGAUGCUCCAGAAACU (forward A), AGUUUCUGGAG-
CAUCGUAG (reverse A), GGCGAUCUUGACUCUGCUG (forward B) and
CAGCAGAGUCAAGAUCGCC (reverse B). Non-silencing siRNAs had the
following sequences AAUUCUCCGAACGUGUCAC (forward) and
GUGACACGUUCGGAGAAUU (reverse). Differentiated HL-60 cells
were transiently transfected with 1 µg of each siRNA using the
Nucleofector apparatus according to the manufacturer's protocol
(Amaxa Biosystems, Cologne, Germany). Transfection efﬁciency was
about 80% when using a Nucleofector V kit with program T-019.
S100A8/A9 siRNA efﬁciency has been conﬁrmed previously [10].
Efﬁciency of iPLA2 siRNA was tested by quantitative real-time PCR, a
technique, which will be explained in the next section.
2.4. Quantitative real-time PCR
First-strand cDNA was prepared from 0.5 µg of total RNA, using the
Thermoscript™ RT-PCR System and 50 ng/µL of random primers
(Invitrogen). Reverse transcription was performed as follows: 10 min
at 25 °C, 50 min at 50 °C and 5 min at 85 °C. Two units of RNase H were
then added and incubated at 37 °C for 20 min. PCRprimers for iPLA2 and
actin were designed based on published sequences in GenBank. Real-
time PCR was performed on a iQ™5 Real-Time PCR Detection System
using iQ™SYBR® Green supermix (Bio-Rad, Herkules, CA, USA) and
cDNA synthesized as described above. PCR was performed in a 20 µL
reaction volume containing 3 µL of cDNA and 1 µL iPLA2, or actin-
speciﬁc primer pair. Primer sequences for actin were TGACCCAGAT-
CATGTTTGAGA (forward) and AGTCCATCACGATGCCAGT (reverse) and
for iPLA2 ATGTCGAAAGACAACGTGGA (forward) and CTCAGCAGAGT-
CAAGATCGC (reverse). Cycling conditions consisted of enzyme activa-
tion for 3 min at 95 °C followed by denaturation at 95 °C for 15 s and
annealing at 60 °C for 30 s (40 cycles). Conditions were optimized to
certify similar ampliﬁcation efﬁciencies for all products. All experiments
were repeated aminimum of three times. Expression level of iPLA2 (Ct)
was normalized against the level of mRNA of a housekeeping gene
(actin) determined in each sample (ΔCt=Ct S100A8/A9−Ctactin).ΔCt can
be converted into relative RNA expression level (2−ΔΔCt) presuming
100% efﬁciency for each PCR cycle [29].
2.5. Fluorescence measurements
H2O2 production was measured by a ﬂuorescence technique as
described in Bueb et al. [30] using a Quantamaster spectroﬂuorimeter
QM-8/2003 (Photon Technology International, Inc., Lawrenceville, NJ,
USA). DMSO-differentiated HL-60 cells were loaded with different
concentrations of BAPTA-AM or DMSO in PSS containing 0.02%
pluronic acid for 30 min at 37 °C, washed three times and resus-
pended in PSS. 30 µM Amplex Red and 1 U/mL HRP were added
during cell incubation, which lasted for 10 min at 37 °C. Cells were
then placed in the spectroﬂuorimeter. Here, H2O2 production was
measured after stimulation by fMLF (1 µM). The H2O2 production of
non-silencing siRNA and S100A8/A9 siRNA transfected cells was
normalized with respect to their respective controls, which corre-
sponded to the 0 µM BAPTA condition.
2.6. Confocal microscopy
Differentiated HL-60 cells were harvested and washed. 3×105 cells
were then placed on the coverslips and centrifuged for 5 min at 300 g.
After stimulation using different compounds, the cells were ﬁxed in a
PBS, which contained 3% w/v paraformaldehyde/2% w/v sucrose, for
15 min at 4 °C. The cells were then washed and permeabilized with a
physiological buffer containing 0.1% Triton X-100 and blocked with
human IgGs for 15 min. The primary antibodyMac387 (DAKO, Glostrup,
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also the S100A8/A9 complex, was applied to the cells at 1:200 dilution
for 45 min at room temperature. A mouse serum (Jackson Immuno
Research, Newmarket Suffolk, UK) was used as a negative control in
order to observe unspeciﬁc labeling of the detection system. The cells
were washed three times and then incubated with a cyanin™2-
conjugated donkey anti-mouse secondary antibody (Jackson Immuno
Research). The coverslips were washed four times, mounted inMoviol/
DABCO and stored for 12 h at 4 °C in the dark. Fluorescence imageswere
acquired using the laser-scanning confocal microscope LSM510 (Carl
Zeiss, Zaventem, Belgium) with a 488 nm laser and a band pass BP505–
550 nm to respectively excite and detect cyanin™2.
2.7. Confocal microscopy quantiﬁcation
All confocal microscopy images were taken with a LSM 510
confocal microscope where the pinhole was adjusted to 1 Airy unit
and using a Plan-Apochromat 63×/1.40 DIC oil objective (Carl Zeiss).
A minimum of 100 cells in total were counted per condition. Imaged
dHL-60 cells, stimulated (test) with different agonists (fMLF,
thapsigargin, PMA) under different calcium conditions (±extracellu-
lar Ca2+ or ±BAPTA-AM), were quantiﬁed in terms of cells displaying
a positive (S100 pos) or negative (S100 neg) S100A8/A9 plasma
membrane translocation. Results are normalized with respect to their
control (ctrl) using the following formula:
Fold induction =
S100pos ðtestÞ
S100pos ðtestÞ + S100neg ðtestÞ
h i = S100pos ðctrlÞ½S100pos ðctrlÞ + S100neg ðctrlÞ
:
With respect to the dHL-60 cells treated with kinase or phospho-
lipase inhibitors (inhib) or without inhibitors (ctrl), images of dHL-60
displaying a positive S100A8/A9 plasmamembrane translocation were
counted and normalized to cells stimulated with (w fMLF) or without
(w/o fMLF) fMLF by using the following formula:
%Translocation =
HL60 ðinhibÞ ðwfMLFÞ−HL60 ðinhibÞ ðw=o fMLFÞ
HL60 ðctrlÞ ðwfMLFÞ−HL60 ðctrlÞ ðw=o fMLFÞ
× 100:
2.8. p38 MAPK assay
The p38 MAPK activity was measured by using the p38 MAPK
activity kit according to the manufacturer's protocol (Cell Signaling
Technology, Danvers, MA, USA). Brieﬂy, cells were pre-treated for
30 min at 37 °C with kinase or phospholipase inhibitors and then
stimulated for 1 min with fMLF. After cell lysis, phosphorylated p38
MAPK was immunoprecipitated with a phospho p38 MAPK antibody
from 200 µg of lysate. The immune complex was washed and
resuspended in a kinase buffer containing 200 µM ATP and 1 µg of
recombinant activating factor-2 (ATF-2) as a p38MAPK substrate. The
reaction was carried out at 30 °C for 30 min and terminated by adding
an SDS sample buffer. The kinase reaction was analyzed by Western
blotting with a phospho-speciﬁc ATF-2 antibody.
2.9. Metabolic labeling
Phosphorylation of S100A9 was investigated by metabolic labeling
of differentiated HL-60 cells with inorganic [32P]-phosphate (Hartman
Analytics, Braunschweig, Germany). 10×106 cells were incubated in a
phosphate-free buffer (HEPES 20 mM, glucose 5.5 mM, CaCl2 1.8 mM,
KCl 5.4 mM, NaCl 137 mM, 1% (w/v) BSA, pH 7.2) for 1 h. Thereafter,
the cells were incubated with 40 µCi [32P]-phosphate. After 60 min of
incubation, the inhibitors were added for 30 min. Then the cells were
stimulated by fMLF. Phosphate incorporation into proteins was
detected by phosphorimaging of the dried gel (GE Healthcare,Buckinghamshire, UK) after immunoprecipitation of S100A9 (with
Mac387 antibody) and sample migration by SDS-PAGE (16% Tricine
pre-cast gel from Invitrogen). Equal loading of immunoprecipitated
S100A9 was conﬁrmed by Western blotting using afﬁnity puriﬁed
rabbit antisera monospeciﬁc for S100A9 (kindly provided by
Dr T. Vogl).2.10. iPLA2 assay
iPLA2 activity was measured using a kit from Cayman Chemicals
following the manufacturer's instructions (Cayman Chemicals, Ann
Arbor, MI, USA). After appropriate treatment and centrifugation of the
cells, the pellets were resuspended in 1 mL of cold buffer (50 MHepes,
pH 7.4, containing 1 mM EDTA) and sonicated. Cell lysates were
centrifuged at 100000 rpm for 15 min at 4 °C. 10 µl of the lysate were
added to a 96 well microtiter plate followed by 5 µL of assay buffer
(80 mMHepes pH 7.4, 150 mMNaCl, 4 mMTritonX-100, 30% glycerol,
and 1 mg/mLBSA). The reactionwas initiated by the addition of 200 µl
of arachidonoyl thiophosphatidylcholin dissolved in 2× assay buffer
and incubated at room temperature for 60 min. The reaction was
terminated by adding 10 µl of 25 mM 5,5-dithio-bis(2-nitrobenzoic
acid), 475 mM EGTA in 0.5 M Tris–HCl pH 8.0. The absorbance was
measured at 414 nm in a sunrise microtiter plate reader (TECAN,
Mechelen, Belgium). iPLA2 activity was ﬁrst normalized with respect
to the protein content of each sample and then expressed as the fold
induction as compared to non-stimulated control.2.11. Statistics
Values obtained from the different cell batches were expressed as
the mean±standard error of the mean (SEM), where n≥3. Statistical
analysis was performed using the Prism5 software (Graph Pad
Software, La Jolla, CA, USA). An analysis of the variance, ANOVA,
was followed by the Newman–Keuls pairwise comparison test for
multiple sets of data or by the Student's t-test for the comparison of
only two sets of data. Values of pb0.05 indicate that the difference
between the means should be considered statistically signiﬁcant. In
the ﬁgures presented in the following section, asterisks indicate the
level of signiﬁcance: * = pb0.05; ** = pb0.01; *** = pb0.001.3. Results
3.1. Relationship between S100A8/A9 complex, [Ca2+]i elevation andNOX2
activation in differentiated HL-60 cells
We investigated S100A8/A9 as a possible link between Ca2+
elevation and H2O2 production in neutrophil-like DMSO-differentiat-
ed HL-60 cells by measuring H2O2 production in scrambled or
S100A8/A9 siRNA transfected cells in different [Ca2+]i conditions by
using increasing concentrations of the [Ca2+]i chelator BAPTA. H2O2
production of non-silencing siRNA and S100A8/A9 siRNA transfected
cells (Fig. 1A) were expressed as % of their respective controls (0 µM
BAPTA). In control siRNA transfected cells our results indicate that by
increasing BAPTA concentrations up to 3 µM, H2O2 production is fully
inhibited, suggesting the Ca2+-dependence of H2O2 production
(Fig. 1A). Moreover the transfection of S100A8/A9 siRNA incubated
without BAPTA leads to a 40% inhibition of H2O2 production (Fig. 1
insert), when compared to the control siRNA transfected cells,
conﬁrming the importance of S100A8/A9 for NOX2 activation in
dHL-60 cells. In the S100A8/A9 siRNA transfected cells, the BAPTA
curve shows that H2O2 production is inhibited at low BAPTA
concentrations (0.01 µM–0.3 µM), indicating a link between
S100A8/A9 and [Ca2+]i for NOX2 activation.
Fig. 1. Ca2+ dependence of S100A8/A9 translocation and S100A8/A9 dependence of NOX2 activity. A) Measurement of H2O2 production. Differentiated HL-60 (dHL-60) cells were
transiently transfected with S100A8 and S100A9 or non-silencing siRNA (control siRNA). After 48 h, cells were tested for fMLF (1 µM)-induced H2O2 production in the presence of
increasing concentrations of BAPTA (0.01–10 µM). H2O2 production is expressed as a percentage (%) of the control (0 µM BAPTA). The results are expressed asmean±SEM. Asterisks
(*/**/***) indicate that the sample is signiﬁcantly different from control with the following levels of statistical signiﬁcance: * = pb0.05; *** = pb0.01; *** = pb0.001). Insert: H2O2
production was measured 48 h after S100A8/A9 or control siRNA transfection and represented as % of control (control siRNA transfected cells). Results are expressed as mean±SEM
and two asterisks, **, indicate that the sample is signiﬁcantly different from the control. B) Immunoﬂuorescent labeling of S100A8/A9. dHL-60 cells were incubated in the presence
(upper panels) or absence (lower panels) of extracellular Ca2+ (1.25 mM) or with BAPTA (3 µM) (upper right panel). Then, cells were stimulated with fMLF (1 µM) (upper middle,
right panel and lower left panel), thapsigargin (0.1 µM) (lower right panel) or DMSO as control (upper left panel). S100A8/A9 were stained by the monoclonal antibody Mac387
followed by a cyanin™2-labeled secondary antibody. C) Quantiﬁcation of S100A8/A9 translocation was determined as described in Section 2, Materials and methods. In this graph,
the asterisks, ***, indicate that the sample is signiﬁcantly different from control (DMSO-treated cells) with a probability less than 0.001 (pb0.001).
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Fig. 2. S100A8/A9 translocation is dependent on p38 MAPK-mediated S100A9
phosphorylation. p38 MAPK activity was measured by using the p38 MAPK activity
kit from Cell Signaling Technology (as described in Section 2, Materials and methods).
A) dHL-60 cells were stimulated with fMLF (1 µM) or DMSO as control after
pretreatment for 30 min with either genistein (100 µM) or SB203580 (10 µM). The
immunoprecipitated p38 MAPK was resuspended in kinase buffer containing ATP and
recombinant ATF-2. Phospho-ATF-2 was detected by Western blotting using an anti-
phospho-ATF-2 antibody and the input of the reaction was determined by measuring
total p38 MAPK. B) The amount of phospho-ATF-2 was normalized with respect to the
input of total p38 MAPK and compared to the control (DMSO-treated cells). C) S100A9
phosphorylation was investigated by metabolic labeling of cells with inorganic [32P]-
phosphate. Cells were stimulated with fMLF (1 µM) or DMSO as control in the presence
of either genistein (100 µM) or SB203580 (10 µM). Equal loading of immunoprecipi-
tated S100A9 was tested by Western blotting using afﬁnity puriﬁed rabbit antisera
monospeciﬁc for S100A9. Graph D corresponds to the quantiﬁcation of the S100A8/A9
translocation determined as described in Section 2, Materials and methods. Three
asterisks, ***, indicate that the sample is signiﬁcantly different from the control (fMLF-
stimulated cells), with a probability less than 0.001 (pb0.001).
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translocation
Previous studies [20,21] have indicated that S100 translocation is
dependent on Ca2+. Moreover, since our data established that NOX2
activation acquired Ca2+ sensitivity via S100A8/A9, it is possible that
the S100A8/A9 complex, through its Ca2+-dependent translocation to
the plasmamembrane, may act as a ‘molecular switch’ between [Ca2+]i
elevation and NOX2 activation. To test this hypothesis, we incubated
dHL-60 cells with or without BAPTA and monitored the endogenous
S100A8/A9 translocation by confocal immunoﬂuorescence. In the non-
stimulated cells, S100A8/A9 is homogeneously distributed within the
cytosol (Fig. 1B control). fMLF (1 µM) stimulation resulted in a 3.5 fold
increased recruitment of S100A8/A9 to the plasma membrane (Fig. 1B
upper middle panel and 1C). Incubation with BAPTA (3 µM,
corresponding to themaximal inhibition ofH2O2 production)prevented
the fMLF-stimulated S100A8/A9 redistribution (Fig. 1B upper right
panel and 1C). We conclude that [Ca2+]i elevations are thus necessary
for S100A8/A9 relocalization at the plasma membrane.
In neutrophils, [Ca2+]i elevation results from an intracellular or
extracellular Ca2+ mobilization either through the internal store
depletion or Ca2+ inﬂux [31]. To identify Ca2+ pools implicated in
S100A8/A9 translocation, we stimulated dHL-60 cells with fMLF (1 µM)
in the absence of extracellular Ca2+. In these conditions, although
S100A8/A9 translocation is partially decreased, a signiﬁcant membrane
recruitment of the S100A8/A9 complex is still observed (Fig. 1B lower left
panel and 1C), providing evidence that intracellular Ca2+ store depletion
can be sufﬁcient for a membrane redistribution of S100 complex. On the
otherhand, apassiveCa2+release fromthe internal storesby thapsigargin
[32] in extracellular Ca2+-free conditionswas not able to induce S100A8/
A9 membrane recruitment (Fig. 1B lower right panel and 1C). The same
result was obtained when cells were stimulated by thapsigargin in
presence of 1.25 µM of Ca2+ (data not shown). Taken together, these
results indicate that [Ca2+]i elevation via store depletion is necessary, but
probably not sufﬁcient, for S100A8/A9 complex membrane recruitment.
3.3. S100A9 phosphorylation by p38 MAPK is involved in the S100A8/A9
translocation
Given thatCa2+release fromthe stores is necessarybutnot sufﬁcient
for S100 complex translocation, we assume that an additional signal is
required for S100A8/A9 redistribution. Since it has been established
that S100A9 canbephosphorylatedonThr 113byp38MAPK [23,24],we
questioned whether the phosphorylation of S100A9 by p38 MAPK is
involved in S100A8/A9 translocation. To test this hypothesis, we used a
pharmacological approach to study the S100A8/A9 translocation after
treatment with the tyrosine kinase inhibitor genistein or the p38MAPK
inhibitor SB203580. Decrease of S100A9 phosphorylation by genistein
(100 µM) was accompanied by inhibition of S100A8/A9 translocation
(80±4%) (Fig. 2C and D), conﬁrming the correlation between S100A9
phosphorylation andS100A8/A9 translocation. Furthermore, p38MAPK
activity inhibitionbySB203580 (10 µM) (Fig. 2AandB) also resulted in a
decrease of S100A9 phosphorylation, which was associated with a
reduction of S100A8/A9 membrane recruitment (60±4%). We can
conclude that in addition to the internal Ca2+ store release, p38 MAPK-
mediated phosphorylation of S100A9 is involved in S100A8/A9
complex redistribution to the plasma membrane.
3.4. iPLA2 is a novelmediator of S100A8/A9 translocationandNOX2activity
Our results establish that S100A8/A9 complex modulates NOX2
activity through p38 MAPK-dependent and intracellular Ca2+ store
depletion-dependent translocation of the S100 complex. In a previous
study, Beckett et al. suggested that p38 MAPK activation occurs
downstream of iPLA2 activation [26] in myocytes. Therefore, we
suppose that iPLA2-mediated p38 MAPK activation is involved in
Fig. 3. NOX2 activity is dependent on iPLA2. A) iPLA2 activity was measured by using the
iPLA2 assay kit fromCayman chemicals (as described in Section 2,Materials andmethods).
dHL-60 cells were stimulated with fMLF (1 µM) or DMSO as control in the absence or
presence of BEL (10 µM). Results were normalized with respect to the control (DMSO-
treated cells) and expressed as mean±SEM. In all the graphs of this ﬁgure, two asterisks,
**, indicate that the sample is signiﬁcantly different from the controlwith a probability less
than0.01(pb0.01) and three asterisks ***, indicate that the sample is signiﬁcantlydifferent
from the control with a probability less than 0.001 (pb0.001). B) H2O2 production was
measured by a spectroﬂuorimetric method after incubation for 30 min with increasing
concentrations of BEL (1–30 µM). Results are expressed as% of control (0 µMBEL). C) dHL-
60 cells were transiently transfected with iPLA2 or non-silencing siRNA (control). After
48 h, cells were tested for fMLF (1 µM)-inducedH2O2 production. Results are expressed as
% of control. Efﬁciency of iPLA2 siRNA tested by quantitative real-time PCR is shown in
insert. Data were normalized to actin and expressed relative to the control (non-silencing
siRNA). Results are expressed as mean±SEM.
Fig. 4. S100A8/A9 translocation is dependent on iPLA2. Immunoﬂuorescent labeling of
S100A8/A9. A) dHL-60 cells were stimulated with fMLF (1 µM) after pretreatment of the
cellswith BEL (10 µM) orwithout BEL (control). B) Cells were transiently transfectedwith
iPLA2 or non-silencing siRNA (control). After 48 h, cells were stimulatedwith fMLF (1 µM)
orDMSOascontrol. C)Quantiﬁcationof S100A8/A9 translocation asdescribed inSection2,
Materials and methods. Three asterisks ***, indicate that the sample is signiﬁcantly
different from the control with a probability less than 0.001 (pb0.001).
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test this hypothesis, we ﬁrst determined whether iPLA2 is activated in
dHL-60 cells and then investigated its potential involvement in NOX2activation. Measurement of iPLA2 activity demonstrated that fMLF-
stimulated dHL-60 cells led to a 2.7 fold increase in iPLA2 activity
(Fig. 3A). Pretreatment of cells with 10 µM bromoenol lactone (BEL), a
selective inhibitor of iPLA2 [33], resulted in a complete inhibition of
fMLF-induced iPLA2 activity (Fig. 3A). These results conﬁrm that iPLA2
is functionally active in dHL-60 cells.
Two independent approaches (pharmacological and siRNA strategy)
were used to determine the role of iPLA2 in NOX2 regulation.
Pretreatment of dHL-60 cells with BEL (10 µM) triggered a concentra-
tion-dependent inhibition of fMLF-induced H2O2 production (83±2%
inhibition, 10 µM BEL) (Fig. 3B). To conﬁrm this result, dHL-60 cells
were transfected with speciﬁc iPLA2 siRNA. As expected, siRNA
decreased iPLA2 RNA expression by 70% when compared to the non-
silencing siRNA transfected control cells (Fig 3C insert). Further, iPLA2
siRNA prevented activation of fMLF-induced NOX2 activation (Fig. 3C).
Similar effects of the siRNA strategy and pharmacological inhibition of
iPLA2-regulated NOX2 activity underline the role of iPLA2 in this process
in dHL-60 cells. These two approaches were also used to determine
Fig. 5. iPLA2 is implicated in the activation of p38 MAPK and phosphorylation of
S100A9. A) Measurement of p38 MAPK activity. dHL-60 cells were stimulated with
fMLF (1 µM) or DMSO as control after treatment of the cells with or without BEL
(10 µM). The phospho-ATF-2 amount was normalized to the input of total p38 MAPK
and compared to the control (DMSO-treated cells). Two asterisks, **, indicate that the
sample is signiﬁcantly different from the non-stimulated control with a probability less
than 0.01 (pb0.01). B) S100A9 phosphorylation determined bymetabolic labeling. Cells
were stimulated with fMLF (1 µM) or DMSO as control after 30 min incubation with or
without BEL (10 µM). Equal loading of immunoprecipitated S100A9 was tested by
Western blotting using afﬁnity puriﬁed rabbit antisera monospeciﬁc for S100A9.
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tion. As shown in Fig. 4A, fMLF-stimulated S100A8/A9 recruitment to
the plasma membrane was inhibited (44±2%) by pretreatment of the
cellswith BEL (10 µM). Similarly, S100A8/A9 translocationwas reduced
(51±4%) after transfection of cells by iPLA2 siRNA (Fig. 4B). Our results
indicate that fMLF-mediated activation of NOX2 is dependent on iPLA2
activation-mediated S100A8/A9 translocation in dHL-60 cells.
To test whether iPLA2 activity is necessary for p38 MAPK activation,
we pre-treated dHL-60 cells with BEL (10 µM) before fMLF (1 µM)
stimulation andmeasuredp38MAPKactivity. As shown in Fig. 5A, fMLF-
activated p38MAPK is prevented by pretreatmentwith BEL. Thus, iPLA2
appears to regulate fMLF-stimulated p38MAPK activity in dHL-60 cells.
Besides, 32P metabolic labeling showed a decrease of fMLF-stimulated
S100A9 phosphorylation (Fig. 5B) after BEL pretreatment. These results
demonstrate that S100A8/A9 translocation mediated by p38 MAPK-
induced S100A9 phosphorylation is dependent on iPLA2 and that
activation of p38 MAPK occurs downstream of iPLA.
4. Discussion
S100A8 and S100A9, which are found in high concentrations at local
sites of inﬂammation, are also largely expressed in the cytoplasm of
phagocytes [6,11,34]. These two Ca2+-binding proteins have been
involved in the regulation of NOX2 in a Ca2+-dependent manner [7,8].
Studies regarding the regulation of NOX2 by S100 proteins have largely
been performed in cell-free assays or recombinant systems. Thus
conclusions might be carefully extrapolated to whole cells and even to
human neutrophils. However, the exact regulatorymechanism involving
Ca2+, S100A8/A9 and NOX2 activity is not completely clear. Therefore
fundamental details, in particular the contribution of S100A8/A9 in
the Ca2+-regulated NOX2 activity as well as in the pathway underlying
S100-regulated NOX2 activity, need to be understood. Our present work
investigated the role of S100 A8/A9 in the regulation of NOX2 activity in
neutrophil-likeHL-60 cells.We found that both S100A8/A9 complex and
[Ca2+]i elevation are essential for NOX2 activation in these cells [10].
Themolecularmechanism bywhich S100A8/A9 facilitates the [Ca2+]i
elevation-dependent NOX2 activity is unclear. Previously, it has beenshown that S100A8/A9, through its binding to Ca2+, interacts with
ﬂavocytochrome b558 and mediates its transition from an inactive to an
active conformation state resulting in NOX2 activation [35]. These results
raise the question as to how cytosolic S100A8/A9 localizes towards
the plasma membrane where it combines to NOX2. Clearly, there is
evidence that the S100A8/A9 complex migrates to the membrane
through a Ca2+-dependent mechanism [20–22] but the Ca2+ source
leading to Ca2+ mobilization has not yet been formally identiﬁed. Our
results, based on an immunoﬂuorescence approach, conﬁrm the
importance of [Ca2+]i elevation in S100A8/A9 membrane recruitment
and indicate that Ca2+ released from the internal stores is necessary for
fMLF-induced S100A8/A9 translocation to the plasma membrane in
differentiated HL-60 cells. In addition, a partial reduction of S100A8/A9
translocation is observed after extracellular Ca2+ deprivation. Thus, we
can conclude that although extracellular Ca2+ entry is not crucial for
S100A8/A9 translocation, it appears that it is required for a maximal
translocation, in addition to the Ca2+ emptying from the intracellular
stores. Stimulation of cells with thapsigargin, in the absence of extra-
cellular Ca2+ did not induce the redistribution of S100A8/A9 to the
plasma membrane. While fMLF induces a fast receptor-mediated Ca2+
store depletion ensuring a rapid increase in [Ca2+]i, thapsigargin trig-
gers a passive Ca2+ release from the internal stores and a slow increase
in [Ca2+]i [36,37]. The discrepancy between these two Ca2+ kinetic
processes may explain why the S100A8/A9 complex translocates upon
fMLF and not thapsigargin stimulation. However, we cannot exclude
the possibility that a supplementary signal is necessary for S100A8/A9
translocation to the plasma membrane. This is supported by the fact
that p38 MAPK-mediated S100A9 phosphorylation [23,24] has been
involved in the membrane recruitment of S100A8/A9 in cellular
fractionation experiments [38,39]. IndHL-60cells, ourdatademonstrate
that S100A9 phosphorylation and S100A8/A9 translocation are inhib-
ited after treatment of cells with tyrosin kinase and p38 MAPK inhi-
bitors. This result supports the idea that p38 MAPK-induced S100A9
phosphorylation is necessary for S100A8/A9 relocalization. It could be
envisaged that phosphorylation increases S100A9 afﬁnity for Ca2+ and
therefore favors Ca2+ binding to S100A9 [39] leading to improved
S100A8/A9 translocation to the plasma membrane.
In myocytes there is evidence for p38 MAPK activation by iPLA2
[26], but there is no indication of iPLA2 involvement in S100A9
phosphorylation. We have shown that iPLA2 is required for S100A9
phosphorylation and activation of p38 MAPK is induced by iPLA2 in
dHL-60 cells. Because iPLA2 induces S100A9 phosphorylation through
p38 MAPK, it would be expected that iPLA2 regulates S100A8/A9
translocation and subsequent NOX2 activity. Our data based on the
use of a pharmacological inhibitor and a siRNA strategy support the
hypothesis that iPLA2 controls S100 complex translocation and NOX2
activity. Thus we identify iPLA2 as a newmolecular player in S100A8/
A9 translocation-mediated NOX2 activity. Because PLA2-produced
arachidonic acid has been shown to regulate NOX2 activity [8], most
likely through the process of binding to S100A8/A9 which allows its
transport to the plasma membrane [40], we cannot fully exclude the
possibility that iPLA2 mediates an additional mechanism involved in
the regulation of NOX2 activity and/or S100A8/A9 translocation,
independently of p38 MAPK activity. However, intracellular Ca2+
store depletion, which is involved in S100A8/A9 translocation in dHL-
60 cells, has been suggested to activate iPLA2 [41] through the
production of a diffusible messenger [42]. This mediator has been
identiﬁed as sphingosine-1 phosphate by Itagaki et al. [43] in human
neutrophils. Further investigations will be necessary to determine the
actual relationship between sphingosine-1 phosphate/iPLA2/p38
MAPK leading to S100A8/A9 translocation and NOX2 activation.
In conclusion, we establish that fMLF-induced NOX2 activation
occurs via S100A8/A9 complex translocation to the plasma membrane
resulting from(i) S100A9phosphorylation and (ii) an increaseof [Ca2+]i
induced by intracellular Ca2+ store depletion. Most importantly, our
results here allow us to deﬁne a signal transduction pathway linking
847V. Schenten et al. / Biochimica et Biophysica Acta 1803 (2010) 840–847iPLA2-regulated p38 MAPK activity to S100A8/A9 translocation and
subsequent NOX2 activation.
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